BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 19956808)

  • 1. Dapoxetine: a novel treatment for premature ejaculation.
    Owen RT
    Drugs Today (Barc); 2009 Sep; 45(9):669-78. PubMed ID: 19956808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.
    Russo A; Capogrosso P; Ventimiglia E; La Croce G; Boeri L; Montorsi F; Salonia A
    Int J Clin Pract; 2016 Sep; 70(9):723-33. PubMed ID: 27456527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation.
    Hutchinson K; Cruickshank K; Wylie K
    Drug Saf; 2012 May; 35(5):359-72. PubMed ID: 22452563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial.
    Kaufman JM; Rosen RC; Mudumbi RV; Tesfaye F; Hashmonay R; Rivas D
    BJU Int; 2009 Mar; 103(5):651-8. PubMed ID: 19021601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapoxetine: in premature ejaculation.
    Hoy SM; Scott LJ
    Drugs; 2010 Jul; 70(11):1433-43. PubMed ID: 20614950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel drug for 'on-demand' treatment of premature ejaculation.
    Andersson KE; Mulhall JP; Wyllie MG
    BJU Int; 2006 Feb; 97(2):311-5. PubMed ID: 16430636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine.
    Shabsigh R; Patrick DL; Rowland DL; Bull SA; Tesfaye F; Rothman M
    BJU Int; 2008 Sep; 102(7):824-8. PubMed ID: 18647300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials.
    McMahon CG; Althof SE; Kaufman JM; Buvat J; Levine SB; Aquilina JW; Tesfaye F; Rothman M; Rivas DA; Porst H
    J Sex Med; 2011 Feb; 8(2):524-39. PubMed ID: 21059176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine.
    McMahon C; Kim SW; Park NC; Chang CP; Rivas D; Tesfaye F; Rothman M; Aquilina J;
    J Sex Med; 2010 Jan; 7(1 Pt 1):256-68. PubMed ID: 19878447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapoxetine for premature ejaculation.
    Feige AM; Pinsky MR; Hellstrom WJ
    Clin Pharmacol Ther; 2011 Jan; 89(1):125-8. PubMed ID: 21085116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapoxetine for premature ejaculation.
    McMahon CG
    Expert Opin Pharmacother; 2010 Jul; 11(10):1741-52. PubMed ID: 20540653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials.
    Porst H; McMahon CG; Althof SE; Sharlip I; Bull S; Aquilina JW; Tesfaye F; Rivas DA
    J Sex Med; 2010 Jun; 7(6):2231-2242. PubMed ID: 20412423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials.
    Pryor JL; Althof SE; Steidle C; Rosen RC; Hellstrom WJ; Shabsigh R; Miloslavsky M; Kell S;
    Lancet; 2006 Sep; 368(9539):929-37. PubMed ID: 16962882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case.
    Waldinger MD; Schweitzer DH
    J Sex Med; 2008 Apr; 5(4):966-997. PubMed ID: 18371047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study.
    McMahon CG; Giuliano F; Dean J; Hellstrom WJ; Bull S; Tesfaye F; Sharma O; Rivas DA; Aquilina JW
    J Sex Med; 2013 Sep; 10(9):2312-25. PubMed ID: 23845016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries.
    Buvat J; Tesfaye F; Rothman M; Rivas DA; Giuliano F
    Eur Urol; 2009 Apr; 55(4):957-67. PubMed ID: 19195772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral agents for the treatment of premature ejaculation: review of efficacy and safety in the context of the recent International Society for Sexual Medicine criteria for lifelong premature ejaculation.
    McMahon CG; Porst H
    J Sex Med; 2011 Oct; 8(10):2707-25. PubMed ID: 21771283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dapoxetine for premature ejaculation: Advances in clinical studies].
    Zhou TY; Li YF
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):931-6. PubMed ID: 26665685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation.
    Althof SE; Brock GB; Rosen RC; Rowland DL; Aquilina JW; Rothman M; Tesfaye F; Bull S
    J Sex Med; 2010 Jun; 7(6):2243-2252. PubMed ID: 20367770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central regulation of ejaculation and the therapeutic role of serotonergic agents in premature ejaculation.
    Patel K; Hellstrom WJ
    Curr Opin Investig Drugs; 2009 Jul; 10(7):681-90. PubMed ID: 19579174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.